Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD.
Replication-defective human adenoviruses type 5 (HAd5) expressing the bovine herpesvirus type 1 (BHV-1) glycoprotein gC or gD under the control of the human cytomegalovirus immediate-early promoter/enhancer (AdCMVgC or AdCMVgD) or the 5' regulatory region of the human desmin gene (AdDESMgC or AdDESMgD) were generated. A preliminary experiment performed on rabbits showed that the intranasal administration of AdCMV elicited higher levels of BHV-1 neutralizing antibodies than the intramuscular administration of AdDESM. The obtained results allowed to select the replication-defective AdCMVgC and AdCMVgD for further assessment of their potential as a recombinant vaccine in cattle. Calves were injected intranasally twice 3 weeks apart with either AdCMVgC or AdCMVgD or a combination of these two recombinants or a commercially available live vaccine for comparison. The highest BHV-1 neutralizing antibody titres were obtained with AdCMVgD followed by the live vaccine and to a lower extent with the combination of the two recombinants (AdCMVgC+AdCMVgD). Calves were protected against intranasal BHV-1 challenge performed 3 weeks after the second immunization. In view of the obtained results, recombinant HAd5 may be developed as an intranasal vaccine vector in cattle administrated either alone or sequentially with non-human adenovirus-based vectors.
Gogev
Sacha
S
Laboratory of Virology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, University of Lie'ge, Boulevard de Colonster, 20-B 43 bis, 4000, Sart Tilman-Lie'ge, Belgium.
Vanderheijden
Nathalie
N
Lemaire
Myle'ne
M
Schynts
Frédéric
F
D'Offay
Jean
J
Deprez
Isabelle
I
Adam
Micheline
M
Eloit
Marc
M
Thiry
Etienne
E
D000260:Adenoviruses, Human / Q000235:genetics*; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002417:Cattle; D002460:Cell Line; D003001:Cloning, Molecular; D007242:Herpesvirus 1, Bovine / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007371:Interferon-gamma / Q000096:biosynthesis; D009297:Nasal Mucosa / Q000821:virology; D011817:Rabbits; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics* / Q000276:immunology; D014779:Virus Replication
D000914:Antibodies, Viral; D022283:Herpesvirus Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014764:Viral Proteins; C046998:bovine herpesvirus type-1 glycoproteins; D007371:Interferon-gamma